Implementation of guideline-based lipid reporting and rate of lipid lowering therapy prescription

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Journal of clinical lipidology Pub Date : 2025-03-01 DOI:10.1016/j.jacl.2024.12.012

Anish Adhikari MD , Aya Haghamad PharmD , Xueqi Huang MS , Joanna Fishbein MPH , Georgeta Vaidean MD, MPH, PhD , Jamie S. Hirsch MD , James M. Crawford MD, PhD , Maya Rubin MD , Monique Carrero-Tagle MS , Eugenia Gianos MD

{"title":"Implementation of guideline-based lipid reporting and rate of lipid lowering therapy prescription","authors":"Anish Adhikari MD , Aya Haghamad PharmD , Xueqi Huang MS , Joanna Fishbein MPH , Georgeta Vaidean MD, MPH, PhD , Jamie S. Hirsch MD , James M. Crawford MD, PhD , Maya Rubin MD , Monique Carrero-Tagle MS , Eugenia Gianos MD","doi":"10.1016/j.jacl.2024.12.012","DOIUrl":null,"url":null,"abstract":"<div><div>Lipid goal attainment remains suboptimal due to patient, provider, and system level factors. We aimed to assess whether updated, guideline-based lipid reporting and clinical decision support was associated with different lipid-lowering therapy (LLT) prescription patterns. We conducted a retrospective study in our electronic health record (EHR) comparing prescriptions within 90 days of lab reporting both prior to the reporting change (21,417 patients in 2019-2020) and after (39,866 patients in 2020-2021). We found a significant increase in the initiation of LLT in patients > 40 years of age with low-density lipoprotein cholesterol (LDL-C) ≥ 100  mg/dL, with 2377 (11.6%) initiated prior to compared to 6205 (16.3%) after the reporting change (<em>P</em> < .001). Among 4469 adult patients with atherosclerotic cardiovascular disease and LDL-C ≥ 70 mg/dL prior to (n = 2040) and after (n = 3277) the reporting change, there was a significantly higher rate of LLT initiation, 444 (25.9%) prior to vs 875 (31.8%) after; <em>P</em> < .001. In conclusion, after implementation of updated guideline-based lipid test reporting, we observed higher initiation rates of LLT for indicated patients. Our study suggests that guideline-based reporting of lipid test results may aid in guideline implementation.</div></div>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":"19 2","pages":"Pages 358-363"},"PeriodicalIF":3.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1933287424002988","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Lipid goal attainment remains suboptimal due to patient, provider, and system level factors. We aimed to assess whether updated, guideline-based lipid reporting and clinical decision support was associated with different lipid-lowering therapy (LLT) prescription patterns. We conducted a retrospective study in our electronic health record (EHR) comparing prescriptions within 90 days of lab reporting both prior to the reporting change (21,417 patients in 2019-2020) and after (39,866 patients in 2020-2021). We found a significant increase in the initiation of LLT in patients > 40 years of age with low-density lipoprotein cholesterol (LDL-C) ≥ 100  mg/dL, with 2377 (11.6%) initiated prior to compared to 6205 (16.3%) after the reporting change (P < .001). Among 4469 adult patients with atherosclerotic cardiovascular disease and LDL-C ≥ 70 mg/dL prior to (n = 2040) and after (n = 3277) the reporting change, there was a significantly higher rate of LLT initiation, 444 (25.9%) prior to vs 875 (31.8%) after; P < .001. In conclusion, after implementation of updated guideline-based lipid test reporting, we observed higher initiation rates of LLT for indicated patients. Our study suggests that guideline-based reporting of lipid test results may aid in guideline implementation.

查看原文本刊更多论文

基于指南的血脂报告和降脂率治疗处方的实施。

由于患者、提供者和系统层面的因素，脂质目标的实现仍然不是最佳的。我们的目的是评估更新的、基于指南的脂质报告和临床决策支持是否与不同的降脂治疗（LLT）处方模式相关。我们在电子健康记录（EHR）中进行了一项回顾性研究，比较了报告变更之前（2019-2020年21,417例患者）和之后（2020-2021年39,866例患者）90天内的处方。我们发现，在LDL-C≥100 mg/dL的bbb40岁患者中，开始LLT的人数显著增加，其中2377人（11.6%）在报告改变后开始LLT，而6205人（16.3%）在报告改变前开始

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of clinical lipidology 医学-药学

CiteScore

7.00

自引率

6.80%

发文量

209

审稿时长

49 days

期刊介绍： Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.